Dual interference with novel genes mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice

Human Gene Therapy

Volumn 21, Issue 8, 2010, Pages 969-977

  Gao, Sui ^a   Wang, Ming ^a   Ye, Huali ^a   Guo, Jianwen ^a   Xi, Dong ^a   Wang, Zhimo ^a   Zhu, Chuanglong ^a   Yan, Weiming ^a   Luo, Xiaoping ^b   Ning, Qin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; ENHANCED GREEN FLUORESCENT PROTEIN; PLASMID VECTOR; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; CHO CELL; FIBRIN DEPOSITION; FLUORESCENCE MICROSCOPY; GENE; GENE EXPRESSION; GENE FUSION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; HYDRODYNAMICS; IN VIVO STUDY; LIVER CELL; LIVER NECROSIS; MFGL2 GENE; MTNFR1 GENE; MURINE HEPATITIS CORONAVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STATISTICAL SIGNIFICANCE; SURVIVAL; VIRUS HEPATITIS; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; FIBRINOGEN; GENE EXPRESSION; HYDRODYNAMICS; LIVER FAILURE, ACUTE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MURINE HEPATITIS VIRUS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; THROMBOPLASTIN; TRANSCRIPTION, GENETIC;

CRICETULUS GRISEUS; MURINE HEPATITIS VIRUS; MURINE HEPATITIS VIRUS STRAIN 3; MUS;

EID: 77955489072     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.177     Document Type: Article

References (35)

1. Amarzguioui, M., and Prydz, H. (2004). An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. 316, 1050-1058.
2. Arvelo, M.B., Cooper, J.T., Longo, C., Daniel, S., Grey, S.T., Ma-hiou, J., Czismadia, E., Abu-Jawdeh, G., and Ferran, C. (2002). A20 protects mice from d-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology 35, 535-543.
3. Bang, S., Jeong, E.J., Kim, I.K., Jung, Y.K., and Kim, K.S. (2000). Fas and tumor necrosis factor-mediated apoptosis uses the same binding surface of FADD to trigger signal transduction: A typical model for convergent signal transduction. J. Biol. Chem. 275, 36217-36222.
4. Chan, M.W., Liu, M., Fung, L., Cole, E.H., Leibowitz, J.L., Marsden, P.A., Clark, D.A., and Levy, G.A. (2002). Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J. Immunol. 168, 5170-5177.
5. Cheng, V.C., Lo, C.M., and Lau, G.K. (2003). Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East. Semin. Liver Dis. 23, 239-250.
6. Coleman, W.B. (2003). Mechanisms of human hepatocarcino-genesis. Curr. Mol. Med. 3, 573-588.
7. Cordeiro, M.F., Mead, A., Ali, R.R., Alexander, R.A., Murray, S., Chen, C., York-Defalco, C., Dean, N.M., Schultz, G.S., and Khaw, P.T. (2003). Novel antisense oligonucleotides targeting TGF inhibit in vivo scarring and improve surgical outcome. Gene Ther. 10, 59-71.
8. Ding, J.W., Ning, Q., Liu, M.F., Lai, A., Leibowitz, J., Peltekian, K.M., Cole, E.H., Fung, L.S., Holloway, C., Marsden, P.A., Yeger, H., Phillips, M.J., and Levy, G.A. (1997). Fulminant hepatic failure in murine hepatitis virus strain 3 infection: Tissue-specific expression of a novel fgl2 prothrombinase. J. Virol. 71, 9223-9230.
9. Ding, J.W., Ning, Q., Liu, M.F., Lai, A., Peltekian, K., Fung, L., Holloway, C., Yeger, H., Phillips, M.J., and Levy, G.A. (1998). Expression of the fgl2 and its protein product (pro-thrombinase) in tissues during murine hepatitis virus strain-3 (MHV-3) infection. Adv. Exp. Med. Biol. 440, 609-618.
10. Hecht, N., Pappo, O., Shouval, D., Rose-John, S., Galun, E., and Axelrod, J.H. (2001). Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol. Ther. 3, 683-687.
11. Heering, J., Erlmann, P., and Olayioye, M.A. (2009). Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp. Cell Res. 315, 2505-2514.
12. Higuchi, H., and Gores, G.J. (2003). Mechanisms of liver injury: An overview. Curr. Mol. Med. 3, 483-490.
13. Khvorova, A., Reynolds, A., and Jayasena, S.D. (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209-216.
14. Kim, D.H., Behlke, M.A., Rose, S.D., Chang, M.S., Choi, S., and Rossi, J.J. (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222-226.
15. Ledgerwood, E.C., Pober, J.S., and Bradley, J.R. (1999). Recent advances in the molecular basis of TNF signal transduction. Lab. Invest. 79, 1041-1050.
16. Leibowitz, J.L., and Belyavskaya, E. (2001). Caspase inhibitors block MHV-3 induced apoptosis and enhance viral replication and pathogenicity. Adv. Exp. Med. Biol. 494, 109-114.
17. Leist, M., Gantner, F., Bohlinger, I., Germann, P.G., Tiegs, G., and Wendel, A. (1994). Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-a requires transcription arrest. J. Immunol. 153, 1778-1788.
18. Levy, G.A., Liu, M., Ding, J., Yuwaraj, S., Leibowitz, J., Marsden, P.A., Ning, Q., Kovalinka, A., and Phillips, M.J. (2000). Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am. J. Pathol. 156, 1217-1225.
19. Li, C., Fung, S., Crow, A., Mysers-Mason, N., Philips, M., Lei-bowitz, J., Cole, E., Ottaway, C., and Levy, G. (1992). Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection. J. Exp. Med. 176, 689-697.
20. Liu, M., Mendicino, M., Ning, Q., Ghanekar, A., He, W., McGilv-ray, I., Shalev, I., Pivato, D., Clark, D.A., Phillips, M.J., and Levy, G.A. (2006). Cytokine-induced hepatic apoptosis is dependent on FGL2/fibroleukin: The role of Sp1/Sp3 and STAT1/PU.1 composite cis elements. J. Immunol. 176, 7028-7038.
21. Ma, Y., Chan, C.Y., and He, M.L. (2007). RNA interference and antiviral therapy. World J. Gastroenterol. 13, 5169-5179.
22. Marsden, P.A., Ning, Q., Fung, L.S., Luo, X., Chen, Y., Mendi-cino, M., Ghanekar, A., Scott, J.A., Miller, T., Chan, C.W., Chan, M.W., He, W., Gorczynski, R.M., Grant, D.R., Clark, D.A., Phillips, M.J., and Levy, G.A. (2003). The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J. Clin. Invest. 112, 58-66.
23. McCaffrey, A.P., Meuse, L., Karimi, M., Contag, C.H., and Kay, M.A. (2003). A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 38, 503-508.
24. Nakamoto, Y., and Kaneko, S. (2003). Mechanisms of viral hepatitis induced liver injury. Curr. Mol. Med. 3, 537-544.
25. Nakayama, Y., Shimizu, Y., Hirano, K., Ebata, K., Minemura, M., Watanabe, A., and Sugiyama, T. (2005). Sugiyama T CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis. Hepatology 42, 915-924.
26. Ning, Q., Phillips, M.J., and Levy, G.A. (1998). Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the pro-coagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J. Immunol. 160, 3487-3493.
27. Ogasewara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809.
28. Pawlotsky, J.M. (2002). Molecular diagnosis of viral hepatitis. Gastroenterology 122, 1554-1568.
29. Pfeffer, K., Matsuyama, T., Kundig, T.M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P.S., Kronke, M., and Mak, T.W. (1993). Mice deficient for the 55-kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73, 457-467.
30. Pinkoski, M.J., Brunner, T., Green, D.R., and Lin, T. (2000). Fas and Fas ligand in gut and liver. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G354-G366.
31. Schwartz, B.S., Levy, G.A., Fair, D.S., and Edgington, T.S. (1982). Murine lymphoid procoagulant activity induced by bacterial lipopolysaccharide and immune complexes is a monocyte prothrombinase. J. Exp. Med. 155, 1464-1479.
32. Song, E., Lee, S.K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., and Lieberman, J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347-351.
33. Stevenson, M. (2004). Therapeutic potential of RNA interference. N. Engl. J. Med. 351, 1772-1777.
34. Varfolomeev, E.E., Boldin, M.P., Goncharov, T.M., and Wallach, D. (1996). A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor and Fas/APO1: Proteins binding to the death domains of the two receptors also bind to each other. J. Exp. Med. 183, 1271-1275.
35. Zhu, C.L., Sun, Y., Luo, X.P., Yan, W.M., Xi, D., and Ning, Q. (2006). Novel mfgl2 antisense plasmid inhibits mfgl2 expression and ameliorates MHV-3 induced fulminant hepatitis in BALB/cJ mice. Hum. Gene Ther. 17, 589-600.